Published in Mol Ther on April 19, 2011
RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov (2012) 3.70
Targeting RNA to treat neuromuscular disease. Nat Rev Drug Discov (2011) 1.89
Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol Ther Nucleic Acids (2012) 1.53
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug Chem (2011) 1.32
Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis Model Mech (2015) 1.30
Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve (2013) 1.14
A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther (2013) 1.00
Persistent dystrophin protein restoration 90 days after a course of intraperitoneally administered naked 2'OMePS AON and ZM2 NP-AON complexes in mdx mice. J Biomed Biotechnol (2012) 0.97
Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther (2014) 0.97
Progress in gene therapy of dystrophic heart disease. Gene Ther (2012) 0.96
The chemistry and biology of oligonucleotide conjugates. Acc Chem Res (2012) 0.95
Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. Mol Ther Nucleic Acids (2012) 0.95
Splicing therapy for neuromuscular disease. Mol Cell Neurosci (2013) 0.95
Exon skipping and gene transfer restore dystrophin expression in human induced pluripotent stem cells-cardiomyocytes harboring DMD mutations. Stem Cells Dev (2013) 0.95
Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. Hum Mol Genet (2015) 0.95
Prevention of exercised induced cardiomyopathy following Pip-PMO treatment in dystrophic mdx mice. Sci Rep (2015) 0.94
Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy. Hum Mol Genet (2013) 0.94
Antisense therapy in neurology. J Pers Med (2013) 0.87
Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res (2013) 0.86
Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy. Proc Natl Acad Sci U S A (2016) 0.86
Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies. Hum Mol Genet (2015) 0.84
Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases. Nucleic Acid Ther (2014) 0.83
Bioconjugates for targeted delivery of therapeutic oligonucleotides. Adv Drug Deliv Rev (2015) 0.83
Parallel synthesis of cell-penetrating peptide conjugates of PMO toward exon skipping enhancement in Duchenne muscular dystrophy. Nucleic Acid Ther (2014) 0.83
Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Sci Rep (2015) 0.81
Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry. Chem Commun (Camb) (2013) 0.81
Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo. Org Biomol Chem (2013) 0.80
Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy. Hum Gene Ther (2013) 0.80
Effective dystrophin restoration by a novel muscle-homing peptide-morpholino conjugate in dystrophin-deficient mdx mice. Mol Ther (2014) 0.79
Implications for Cardiac Function Following Rescue of the Dystrophic Diaphragm in a Mouse Model of Duchenne Muscular Dystrophy. Sci Rep (2015) 0.79
Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency. Mol Ther Nucleic Acids (2013) 0.78
Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy. PLoS One (2014) 0.77
Covalent conjugation of oligonucleotides with cell-targeting ligands. Bioorg Med Chem (2013) 0.77
Identification of a Peptide for Systemic Brain Delivery of a Morpholino Oligonucleotide in Mouse Models of Spinal Muscular Atrophy. Nucleic Acid Ther (2017) 0.77
Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy. Expert Opin Orphan Drugs (2015) 0.75
Targeting mRNA for the treatment of facioscapulohumeral muscular dystrophy. Intractable Rare Dis Res (2016) 0.75
Fructose Promotes Uptake and Activity of Oligonucleotides With Different Chemistries in a Context-dependent Manner in mdx Mice. Mol Ther Nucleic Acids (2016) 0.75
Circulating Biomarkers for Duchenne Muscular Dystrophy. J Neuromuscul Dis (2015) 0.75
Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice. Mol Ther Nucleic Acids (2017) 0.75
Nanotherapy for Duchenne muscular dystrophy. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.75
Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med (2007) 7.29
Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell (1996) 6.42
Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med (2004) 5.59
Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol (2009) 5.35
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med (2003) 4.03
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature (1990) 3.84
Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med (2006) 3.74
Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A (2001) 2.71
Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther (2008) 2.69
Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet (2003) 2.17
A rat antibody against a structure functionally related to the mouse T-cell receptor/T3 complex. Immunogenetics (1988) 2.13
Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A (2008) 2.06
Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet (2003) 1.88
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet (2008) 1.69
Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther (2007) 1.67
Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res (2008) 1.52
Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther (2009) 1.52
Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol Ther (2007) 1.48
RNA-targeted splice-correction therapy for neuromuscular disease. Brain (2010) 1.36
Serum CK, calcium, magnesium, and oxidative phosphorylation in mdx mouse muscular dystrophy. Muscle Nerve (1988) 1.36
Heart-specific overexpression of CUGBP1 reproduces functional and molecular abnormalities of myotonic dystrophy type 1. Hum Mol Genet (2010) 1.35
A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet (2009) 1.34
Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther (2004) 1.31
Alternative splicing of dystrobrevin regulates the stoichiometry of syntrophin binding to the dystrophin protein complex. Curr Biol (2000) 1.20
PKC inhibition ameliorates the cardiac phenotype in a mouse model of myotonic dystrophy type 1. J Clin Invest (2009) 1.19
Therapeutic modulation of DMD splicing by blocking exonic splicing enhancer sites with antisense oligonucleotides. Ann N Y Acad Sci (2006) 1.12
Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther (2010) 1.10
Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther (2010) 0.98
Tissue slices from adult mammalian hearts as a model for pharmacological drug testing. Cell Physiol Biochem (2009) 0.95
Microbubble stability is a major determinant of the efficiency of ultrasound and microbubble mediated in vivo gene transfer. Ultrasound Med Biol (2009) 0.93
In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J Gene Med (2010) 0.93
Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge. Sci Transl Med (2010) 0.87
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol (2011) 9.68
Axial stretch of rat single ventricular cardiomyocytes causes an acute and transient increase in Ca2+ spark rate. Circ Res (2009) 2.35
Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis (2011) 2.32
Effects of fibroblast-myocyte coupling on cardiac conduction and vulnerability to reentry: A computational study. Heart Rhythm (2009) 2.05
miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA (2007) 1.90
Electrical coupling of fibroblasts and myocytes: relevance for cardiac propagation. J Electrocardiol (2005) 1.75
Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc (2012) 1.70
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet (2008) 1.69
Requirement of neuronal- and cardiac-type sodium channels for murine sinoatrial node pacemaking. J Physiol (2004) 1.59
Expression analysis in multiple muscle groups and serum reveals complexity in the microRNA transcriptome of the mdx mouse with implications for therapy. Mol Ther Nucleic Acids (2012) 1.53
Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res (2008) 1.52
Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev (2007) 1.47
Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res (2005) 1.44
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids (2012) 1.41
Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res (2010) 1.41
Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J Control Release (2005) 1.38
RNA-targeted splice-correction therapy for neuromuscular disease. Brain (2010) 1.36
A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet (2009) 1.34
Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res (2007) 1.28
Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. Nucleic Acids Res (2005) 1.27
Ca2+ influx through mechanosensitive channels inhibits neurite outgrowth in opposition to other influx pathways and release from intracellular stores. J Neurosci (2006) 1.25
RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells Mol Dis (2006) 1.22
The biogenesis and characterization of mammalian microRNAs of mirtron origin. Nucleic Acids Res (2011) 1.20
Novel RNA-based strategies for therapeutic gene silencing. Mol Ther (2010) 1.20
Diaphragm rescue alone prevents heart dysfunction in dystrophic mice. Hum Mol Genet (2010) 1.19
Accelerating the design of biomimetic materials by integrating RNA-seq with proteomics and materials science. Nat Biotechnol (2013) 1.18
The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials (2012) 1.16
Cardiac myocyte-nonmyocyte electrotonic coupling: implications for ventricular arrhythmogenesis. Heart Rhythm (2006) 1.11
Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther (2010) 1.10
MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst (2006) 1.10
MicroRNA fate upon targeting with anti-miRNA oligonucleotides as revealed by an improved Northern-blot-based method for miRNA detection. RNA (2011) 1.02
Cardiosphere-derived cells improve function in the infarcted rat heart for at least 16 weeks--an MRI study. PLoS One (2011) 1.02
A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther (2013) 1.00
Role of the 293b-sensitive, slowly activating delayed rectifier potassium current, i(Ks), in pacemaker activity of rabbit isolated sino-atrial node cells. Cardiovasc Res (2002) 1.00
Synthesis of peptide-oligonucleotide conjugates with single and multiple peptides attached to 2'-aldehydes through thiazolidine, oxime, and hydrazine linkages. Bioconjug Chem (2002) 1.00
Chemical structure requirements and cellular targeting of microRNA-122 by peptide nucleic acids anti-miRs. Nucleic Acids Res (2011) 1.00
Optimization of peptide nucleic acid antisense oligonucleotides for local and systemic dystrophin splice correction in the mdx mouse. Mol Ther (2010) 0.98
In vivo MRI characterization of progressive cardiac dysfunction in the mdx mouse model of muscular dystrophy. PLoS One (2012) 0.98
PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res (2011) 0.97
Tissue slices from adult mammalian hearts as a model for pharmacological drug testing. Cell Physiol Biochem (2009) 0.95
Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA. Mol Ther Nucleic Acids (2012) 0.95
Disulfide conjugation of peptides to oligonucleotides and their analogs. Curr Protoc Nucleic Acid Chem (2006) 0.93
Myocardial tissue slices: organotypic pseudo-2D models for cardiac research & development. Future Cardiol (2009) 0.93
In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J Gene Med (2010) 0.93
A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. Oligonucleotides (2003) 0.92
A peptide-based dendrimer that enhances the splice-redirecting activity of PNA conjugates in cells. Bioconjug Chem (2009) 0.92
Fibroblast-myocyte connections in the heart. Heart Rhythm (2011) 0.92
Cell-penetrating peptides do not cross mitochondrial membranes even when conjugated to a lipophilic cation: evidence against direct passage through phospholipid bilayers. Biochem J (2004) 0.91
Loop-loop interaction of HIV-1 TAR RNA with N3'-->P5' deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc Natl Acad Sci U S A (2002) 0.91
Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224. Nucleic Acids Res (2012) 0.90
Pyrenemethyl ara-uridine-2'-carbamate: a strong interstrand excimer in the major groove of a DNA duplex. Chembiochem (2003) 0.90
2'-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry (2002) 0.90
Small RNA-Mediated Epigenetic Myostatin Silencing. Mol Ther Nucleic Acids (2012) 0.89
Lipoplex and peptide-based strategies for the delivery of steric-block oligonucleotides. Int J Pharm (2007) 0.89
Synthesis and biological activity of phosphonoacetate- and thiophosphonoacetate-modified 2'-O-methyl oligoribonucleotides. Org Biomol Chem (2011) 0.89
Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy. Mol Ther Nucleic Acids (2012) 0.89
Targeting the HIV-1 RNA leader sequence with synthetic oligonucleotides and siRNA: chemistry and cell delivery. Biochim Biophys Acta (2005) 0.88
Spatial regulation of intracellular pH in multicellular strands of neonatal rat cardiomyocytes. Cardiovasc Res (2009) 0.88
Exploiting cell surface thiols to enhance cellular uptake. Trends Biotechnol (2012) 0.88
Overview of alternative oligonucleotide chemistries for exon skipping. Methods Mol Biol (2012) 0.88
Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Artif DNA PNA XNA (2012) 0.87
Synthesis and splice-redirecting activity of branched, arginine-rich peptide dendrimer conjugates of peptide nucleic acid oligonucleotides. Bioconjug Chem (2010) 0.87
Use of carbonyl group addition--elimination reactions for synthesis of nucleic acid conjugates. Bioconjug Chem (2005) 0.86
Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells. Nucleic Acids Res (2013) 0.86
Antiviral activity of steric-block oligonucleotides targeting the HIV-1 trans-activation response and packaging signal stem-loop RNAs. Nucleosides Nucleotides Nucleic Acids (2005) 0.85
Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide. RNA (2009) 0.85
A bi-functional siRNA construct induces RNA interference and also primes PCR amplification for its own quantification. Nucleic Acids Res (2005) 0.84
Oligonucleotide analogs as antiviral agents. Curr Opin Mol Ther (2006) 0.84
Chemical modifications to improve the cellular uptake of oligonucleotides. Curr Top Med Chem (2007) 0.84
Hexitol nucleic acid-containing aptamers are efficient ligands of HIV-1 TAR RNA. Biochemistry (2005) 0.83
Synthesis of oligonucleotide 2'-conjugates via amide bond formation in solution. Bioorg Med Chem Lett (2004) 0.83